ストックスクリーナーアプリを入手
1.26
3.08%
-0.04
前日終値:
$1.30
開ける：
$1.3
24時間の取引高:
2.04M
Relative Volume:
1.28
時価総額：
$285.52M
収益：
-
当期純損益:
$-179.82M
株価収益率:
-0.9474
EPS:
-1.33
ネットキャッシュフロー:
$-159.16M
1週間 パフォーマンス:
-8.70%
1か月 パフォーマンス:
+35.48%
6か月 パフォーマンス:
+38.66%
1年 パフォーマンス:
-3.08%
1日の値動き範囲:
$1.17
$1.3189
1週間の範囲:
$1.17
$1.55
52週間の値動き範囲:
$0.4993
$1.60
Gossamer Bio Inc Stock (GOSS) Company Profile
GOSS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.26 | 285.52M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-05 | 再開されました | Wedbush | Outperform |
| 2023-07-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | JP Morgan | Neutral |
| 2022-09-19 | 開始されました | Wedbush | Outperform |
| 2022-04-18 | 開始されました | Raymond James | Outperform |
| 2022-04-06 | 開始されました | UBS | Buy |
| 2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 再開されました | Piper Sandler | Overweight |
| 2020-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-30 | 開始されました | Berenberg | Buy |
| 2019-03-05 | 開始されました | Barclays | Overweight |
| 2019-03-05 | 開始されました | BofA/Merrill | Buy |
| 2019-03-05 | 開始されました | Evercore ISI | Outperform |
| 2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
You Should Read This Analysis Before Investing in Gossamer Bio Inc (NASDAQ:GOSS) - US Post News
Gossamer Bio Inc (NASDAQ: GOSS) Up 11.11% This Year: What Is Going To Happen Next - Stocks Register
Gossamer Bio regains Nasdaq compliance with bid price - Investing.com
Gossamer Bio Is A Good Speculative 'Buy' On Seralutinib For PAH And PH-ILD (NASDAQ:GOSS) - Seeking Alpha
Understanding Gossamer Bio Inc Inc. (GOSS) Price Performance Through Chart Patterns - The InvestChronicle
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
GOSS Stock Sees Surge of Approximately 15.18% in Last Five Days - Knox Daily
Gossamer Bio Inc (NASDAQ: GOSS) Stock Gained 1.83% Over A Month – Any Room To Run? - Marketing Sentinel
Gossamer Bio showcases seralutinib studies at PVRI Congress - MSN
Insider Alert: Gossamer Bio Awards Massive Stock Options Package Worth $586,500 - StockTitan
Are Smart Investors Making the Right Decision? Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio Inc (GOSS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Octagon Capital Advisors LP Increases Stake in Gossamer Bio Inc - GuruFocus.com
Real-Time Update: Gossamer Bio Inc (GOSS) Stock Navigates the Market with Up-to-Date Data - The News Heater
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -0.97 - The Dwinnex
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Gossamer Bio (NASDAQ:GOSS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Analysts Offer Predictions for Gossamer Bio FY2029 Earnings - MarketBeat
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire
Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Weighs in on Gossamer Bio FY2029 Earnings - Defense World
Vanguard Group Inc Reduces Stake in Gossamer Bio Inc - GuruFocus.com
Gossamer Bio And 2 Other Promising Penny Stocks On US Exchanges - Simply Wall St
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire
Game-Changing PAH Treatment Combo Shows Powerful Synergistic Effects in Latest Clinical Data - StockTitan
Cantor Fitzgerald Estimates Gossamer Bio FY2025 Earnings - Defense World
Brokers Set Expectations for Gossamer Bio FY2025 Earnings - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in December - MarketBeat
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Geode Capital Management LLC - Defense World
Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
3 US Penny Stocks With Market Caps Over $100M - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Increase in Short Interest - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in December - Defense World
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know - MSN
The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Biggest stock gainers and losers on Thursday - The Africa Logistics
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times
XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20M, Adds Phase 3 PAH Drug to Portfolio - StockTitan
Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Inc (GOSS)Monday, Aug 26, 2024 - Smartkarma
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - MSN
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
0.33%
大文字化:
|
ボリューム (24 時間):